If TCZ blunts CRP a lot/ESR a fair bit, how can we pick GCA relapses in pts on TCZ? Cool tech (mass spec w tandem mass tag multiplex) on GiACTA samples. Of 344 candidate proteins, guess what ranked highest? Haptoglobin. Let's validate! @MGHrheumatology #ACR20 ABST0513 @RheumNow https://t.co/ErmqZuf2iu

Better outcomes (ASAS20 and ASAS40 @wk 52) seen in younger pts (possibly lower disease duration) when Secukinumab was given to ankylosing spondylitis pts. Early Dx in #AS! #ACR20 Abstr#0350 https://t.co/EKks0b1upc https://t.co/bxIH9lloI1

• https://meet.acrconvergence.org/meetings/virtual/hqhCmkpwMY8bzrG2j

Still more interesting lessons from GiACTA, this time re: nature of GCA flares on TCZ: - visual manifestation flares were rare - ESR or CRP raised in 3/4 of flares (so not raised in 1/4) Understanding these flares is crucial! Unizony et al @MGHMedicine #ACR20 ABST0516 @RheumNow https://t.co/WVIitov7Ut

Shoutout to @SattuiSEMD and @NavarroMillanMD showing #dementia is lower in #RA pts on bDMARDs compared to csDMARDs using CMS data #ACR20 ABS#0488 @RADoctor @RheumNow https://t.co/1XOV2zqKko

DISCOVER-2 (52 wk study) Guselkumab 100mg q4wk and q8wk for tx of PsA 1️⃣Sustained responses in: ACR20/50/70, PASI90/100, HAQ-DI, MDA/VLDA, QoL 2️⃣Improvement enthesitis/dactylitis 3️⃣No increase rate of serious infection @RheumNow #ACR20 Abs#0506 https://t.co/7MXYTucVZ9

IL-6 blockade for management of irAEs without inhibiting anti cancer immune response. Should these be given prior or concomitantly with ICIs? Some interesting ideas to look up from the cancer and immunotherapy study group. #ACR20 @UTSWNews @ACRheum @RheumNow

More UPA safety studies Abst#0215 shows balanced VTE event rates across UPA doses and comparator groups. Evidence for Dr. Strand to use in #ACR20 Great Debate that VTE may be safe TNF alternative @RheumNow. https://t.co/hByttIxiuX

What's your initial biologic of choice when escalating therapy for PsA patients non-responsive to csDMARDs? @RheumNow #ACR20